Prorok PC - Search Results

1

Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer.

Xu JL, Commins J, Partridge E, Riley TL, Prorok PC, Johnson CC, Buys SS. Xu JL, et al. Among authors: prorok pc. Gynecol Oncol. 2012 Apr;125(1):70-4. doi: 10.1016/j.ygyno.2011.12.440. Epub 2011 Dec 22. Gynecol Oncol. 2012. PMID: 22198243 Free PMC article. Clinical Trial.

2

Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer.

Zurawski VR Jr, Sjovall K, Schoenfeld DA, Broderick SF, Hall P, Bast RC Jr, Eklund G, Mattsson B, Connor RJ, Prorok PC, et al. Zurawski VR Jr, et al. Among authors: prorok pc. Gynecol Oncol. 1990 Mar;36(3):299-305. doi: 10.1016/0090-8258(90)90130-d. Gynecol Oncol. 1990. PMID: 2318438

3

NIH Consensus 1994: screening.

Kramer BS, Gohagan J, Prorok PC. Kramer BS, et al. Among authors: prorok pc. Gynecol Oncol. 1994 Dec;55(3 Pt 2):S20-1. doi: 10.1006/gyno.1994.1335. Gynecol Oncol. 1994. PMID: 7835804 Review.

4

Non-parametric estimation of the post-lead-time survival distribution of screen-detected cancer cases.

Xu JL, Prorok PC. Xu JL, et al. Among authors: prorok pc. Stat Med. 1995 Dec 30;14(24):2715-25. doi: 10.1002/sim.4780142410. Stat Med. 1995. PMID: 8619110

5

Nonparametric estimation of solid cancer size at metastasis and probability of presenting with metastasis at detection.

Xu JL, Prorok PC. Xu JL, et al. Among authors: prorok pc. Biometrics. 1997 Jun;53(2):579-91. Biometrics. 1997. PMID: 9192453

6

Estimating a distribution function of the tumor size at metastasis.

Xu JL, Prorok PC. Xu JL, et al. Among authors: prorok pc. Biometrics. 1998 Sep;54(3):859-64. Biometrics. 1998. PMID: 9750239

7

Estimation of post-lead-time survival under dependence between lead-time and post-lead-time survival.

Xu JL, Fagerstrom RM, Prorok PC. Xu JL, et al. Among authors: prorok pc. Stat Med. 1999 Jan 30;18(2):155-62. doi: 10.1002/(sici)1097-0258(19990130)18:2<155::aid-sim12>3.0.co;2-d. Stat Med. 1999. PMID: 10028136 Clinical Trial.

8

Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors. Preliminary data from the plco cancer screening trial.

Hartge P, Hayes R, Sherman M, Prorok P, Schiffman M, Reding D, Buys S. Hartge P, et al. Ann Epidemiol. 2000 Oct 1;10(7):465. doi: 10.1016/s1047-2797(00)00160-5. Ann Epidemiol. 2000. PMID: 11018385

9

Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the prostate, lung, colon, and ovarian cancer screening trial.

Hartge P, Hayes R, Reding D, Sherman ME, Prorok P, Schiffman M, Buys S. Hartge P, et al. Am J Obstet Gynecol. 2000 Nov;183(5):1232-7. doi: 10.1067/mob.2000.107401. Am J Obstet Gynecol. 2000. PMID: 11084571 Clinical Trial.

10

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Prorok PC, et al. Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S. doi: 10.1016/s0197-2456(00)00098-2. Control Clin Trials. 2000. PMID: 11189684 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

134 results

Search Page